Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Sponsor: AbbVie
Listed as NCT06191744, this PHASE3 trial focuses on Follicular Lymphoma (FL) and remains actively recruiting participants. Sponsored by AbbVie, it has been updated 22 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
22 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
▶ Show 17 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Genmab
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Afula, Israel , Albany, United States , Albuquerque, United States , Alexandroupoli, Greece , Amsterdam, Netherlands , Antony, France , Aomori, Japan , Arnhem, Netherlands , Athens, Greece , Austin, United States and 217 more locations